All In Biotech

Drug Trial Radar · NCT06052813

A Study of BN104 in the Treatment of Acute Leukemia

A PhaseI/II, Multicenter, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the Menin Inhibitor BN104 in the Treatment of Patients With Relapsed/Refractory Acute Leukemia

Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

66

Actual

Start

Oct 19, 2023

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.

Conditions

  • ALL, Adult
  • AML, Adult
  • Acute Leukaemia
  • KMT2A Rearrangement
  • NPM1 Mutation
  • NUP98 Gene Rearrangement
  • Menin Inhibitors

Interventions

  • BN104 monotherapyDrug

    Phase I(adults): Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.

  • BN104 monotherapyDrug

    Phase I(adolescent): Will be administered orally twice daily (approximately every 12 hours)

  • BN104 monotherapy - rp2dDrug

    receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PhaseI Incidence of Dose Dose limiting toxicities(DLTs)Time frame: DLT last 28days(at the end of cycle 1 for each dose)
  2. PhaseI Incidence of serious adverse events(SAEs)Time frame: 36 month
  3. PhaseII efficacy assessmentTime frame: 36 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.